FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2769376007> ?p ?o ?g. }

• W2769376007 endingPage "95" @default.
• W2769376007 startingPage "91" @default.
• W2769376007 abstract "Abundance of PD-L1, the ligand of the anti-cancer immunotherapy target PD-1, is negatively regulated by poly-ubiquitination via the cyclin D–CDK4/cullin 3–SPOP axis and PD-1 blockade treatment in mice improved survival when combined with CDK4/6 inhibitors. Immune checkpoint blockade therapy with PD-1 or PD-L1 inhibitors has been approved for the treatment of several types of cancer, but only a small percentage of patients respond to this from of treatment. Wenyi Wei and colleagues report that the abundance of the PD-L1 protein is negatively regulated during cell cycle progression, in part through the activity of the upstream cyclin D–CDK4–SPOP–FZR1 signalling pathway. CDK4/6 inhibitor treatment increases PD-L1 levels and promotes immune evasion in vitro and in vivo. On the other hand, combined treatment with a CDK4/6 inhibitor and a PD-1 blocker has greater anti-tumour efficacy than treatment with each drug alone in mouse models. This combined approach has the potential to improve the treatment of patients with cancer. Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit1,2. However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood3,4,5. Recent studies revealed that response to PD-1–PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells6,7. Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1–PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D–CDK4 and the cullin 3–SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D–CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1–PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers." @default.
• W2769376007 created "2017-12-04" @default.
• W2769376007 creator A5001079874 @default.
• W2769376007 creator A5011378633 @default.
• W2769376007 creator A5014509439 @default.
• W2769376007 creator A5018128720 @default.
• W2769376007 creator A5019679963 @default.
• W2769376007 creator A5025036383 @default.
• W2769376007 creator A5040980276 @default.
• W2769376007 creator A5045195492 @default.
• W2769376007 creator A5053329886 @default.
• W2769376007 creator A5054586047 @default.
• W2769376007 creator A5055774460 @default.
• W2769376007 creator A5062352362 @default.
• W2769376007 creator A5072484240 @default.
• W2769376007 creator A5072567913 @default.
• W2769376007 creator A5075310347 @default.
• W2769376007 creator A5075888726 @default.
• W2769376007 creator A5079240322 @default.
• W2769376007 date "2017-11-16" @default.
• W2769376007 modified "2023-10-18" @default.
• W2769376007 title "Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance" @default.
• W2769376007 cites W1576485326 @default.
• W2769376007 cites W1942897646 @default.
• W2769376007 cites W1986141453 @default.
• W2769376007 cites W1990427876 @default.
• W2769376007 cites W1994847090 @default.
• W2769376007 cites W2002098580 @default.
• W2769376007 cites W2002973833 @default.
• W2769376007 cites W2004497068 @default.
• W2769376007 cites W2010493387 @default.
• W2769376007 cites W2020330574 @default.
• W2769376007 cites W2023553115 @default.
• W2769376007 cites W2058705034 @default.
• W2769376007 cites W2060070314 @default.
• W2769376007 cites W2063264144 @default.
• W2769376007 cites W2066751026 @default.
• W2769376007 cites W2073452121 @default.
• W2769376007 cites W2075152619 @default.
• W2769376007 cites W2076194625 @default.
• W2769376007 cites W2081406767 @default.
• W2769376007 cites W2096172976 @default.
• W2769376007 cites W2098953839 @default.
• W2769376007 cites W2124427232 @default.
• W2769376007 cites W2126821691 @default.
• W2769376007 cites W2136313650 @default.
• W2769376007 cites W2154626333 @default.
• W2769376007 cites W2171018097 @default.
• W2769376007 cites W2292383635 @default.
• W2769376007 cites W2295526061 @default.
• W2769376007 cites W2330968055 @default.
• W2769376007 cites W2502908858 @default.
• W2769376007 cites W2516619560 @default.
• W2769376007 cites W2547310148 @default.
• W2769376007 cites W2554320328 @default.
• W2769376007 cites W2560367415 @default.
• W2769376007 cites W2581841075 @default.
• W2769376007 cites W2586090195 @default.
• W2769376007 cites W2597613988 @default.
• W2769376007 cites W2624626767 @default.
• W2769376007 cites W2749393946 @default.
• W2769376007 cites W2750328162 @default.
• W2769376007 cites W31151557 @default.
• W2769376007 cites W91182734 @default.
• W2769376007 doi "https://doi.org/10.1038/nature25015" @default.
• W2769376007 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5754234" @default.
• W2769376007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29160310" @default.
• W2769376007 hasPublicationYear "2017" @default.
• W2769376007 type Work @default.
• W2769376007 sameAs 2769376007 @default.
• W2769376007 citedByCount "595" @default.
• W2769376007 countsByYear W27693760072018 @default.
• W2769376007 countsByYear W27693760072019 @default.
• W2769376007 countsByYear W27693760072020 @default.
• W2769376007 countsByYear W27693760072021 @default.
• W2769376007 countsByYear W27693760072022 @default.
• W2769376007 countsByYear W27693760072023 @default.
• W2769376007 crossrefType "journal-article" @default.
• W2769376007 hasAuthorship W2769376007A5001079874 @default.
• W2769376007 hasAuthorship W2769376007A5011378633 @default.
• W2769376007 hasAuthorship W2769376007A5014509439 @default.
• W2769376007 hasAuthorship W2769376007A5018128720 @default.
• W2769376007 hasAuthorship W2769376007A5019679963 @default.
• W2769376007 hasAuthorship W2769376007A5025036383 @default.
• W2769376007 hasAuthorship W2769376007A5040980276 @default.
• W2769376007 hasAuthorship W2769376007A5045195492 @default.
• W2769376007 hasAuthorship W2769376007A5053329886 @default.
• W2769376007 hasAuthorship W2769376007A5054586047 @default.
• W2769376007 hasAuthorship W2769376007A5055774460 @default.
• W2769376007 hasAuthorship W2769376007A5062352362 @default.
• W2769376007 hasAuthorship W2769376007A5072484240 @default.
• W2769376007 hasAuthorship W2769376007A5072567913 @default.
• W2769376007 hasAuthorship W2769376007A5075310347 @default.
• W2769376007 hasAuthorship W2769376007A5075888726 @default.
• W2769376007 hasAuthorship W2769376007A5079240322 @default.
• W2769376007 hasBestOaLocation W27693760072 @default.
• W2769376007 hasConcept C104317684 @default.
• W2769376007 hasConcept C121608353 @default.

• next